- Home
- TVTX vs NRIX Comparison
TVTX vs NRIX Comparison
Compare TVTX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- NRIX
- Stock Information
- Founded
- TVTX 2008
- NRIX 2009
- Country
- TVTX United States
- NRIX United States
- Employees
- TVTX N/A
- NRIX N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- TVTX Health Care
- NRIX Health Care
- Exchange
- TVTX Nasdaq
- NRIX Nasdaq
- Market Cap
- TVTX 1.3B
- NRIX 1.1B
- IPO Year
- TVTX N/A
- NRIX 2020
- Fundamental
- Price
- TVTX $14.92
- NRIX $10.24
- Analyst Decision
- TVTX Strong Buy
- NRIX Strong Buy
- Analyst Count
- TVTX 13
- NRIX 18
- Target Price
- TVTX $33.75
- NRIX $30.39
- AVG Volume (30 Days)
- TVTX 2.0M
- NRIX 1.3M
- Earning Date
- TVTX 05-05-2025
- NRIX 04-08-2025
- Dividend Yield
- TVTX N/A
- NRIX N/A
- EPS Growth
- TVTX N/A
- NRIX N/A
- EPS
- TVTX N/A
- NRIX N/A
- Revenue
- TVTX $233,175,000.00
- NRIX $56,417,000.00
- Revenue This Year
- TVTX $68.31
- NRIX $12.84
- Revenue Next Year
- TVTX $55.65
- NRIX N/A
- P/E Ratio
- TVTX N/A
- NRIX N/A
- Revenue Growth
- TVTX 60.55
- NRIX N/A
- 52 Week Low
- TVTX $5.12
- NRIX $8.18
- 52 Week High
- TVTX $25.29
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- TVTX 37.07
- NRIX 39.72
- Support Level
- TVTX $14.13
- NRIX $9.23
- Resistance Level
- TVTX $15.23
- NRIX $10.17
- Average True Range (ATR)
- TVTX 1.31
- NRIX 1.04
- MACD
- TVTX -0.10
- NRIX 0.15
- Stochastic Oscillator
- TVTX 31.70
- NRIX 53.51
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.